Nurix Therapeutics, Inc. (NRIX)
NASDAQ:NRIX
Want to see NRIX full AI Analyst Report?
NRIX Stock Chart & Stats
$17.51
$0.42(2.22%)
At close: 4:00 PM EST
$17.51
$0.42(2.22%)
Day’s Range― - ―
52-Week Range$8.20 - $22.50
Previous CloseN/A
Volume302.00K
Average Volume (3M)2.15M
Market Cap
$1.76B
Enterprise Value$1.47B
Total Cash (Recent Filing)$540.73M
Total Debt (Recent Filing)$58.66M
Price to Earnings (P/E)―
Beta1.52
Next Earnings
Jul 09, 2026EPS Estimate
-0.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.16
Shares Outstanding103,405,815
10 Day Avg. Volume4,329,085
30 Day Avg. Volume2,148,498
Financial Highlights & Ratios
PEG Ratio-0.94
Price to Book (P/B)2.72
Price to Sales (P/S)17.45
P/FCF Ratio-5.56
Enterprise Value/Market Cap0.83
Enterprise Value/Revenue20.44
Enterprise Value/Gross Profit-14.66
Enterprise Value/Ebitda-5.35
Forecast
1Y Price Target
$33.00Price Target Upside88.46% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.6
Revenue Forecast (FY)$106.68M
Bulls Say, Bears Say
Bulls Say
Strategic Roche Collaboration And FundingA $700M upfront plus up to $2.3B potential aligns a deep-pocket partner with Nurix, materially extending runway and de-risking late-stage development. Roche’s cost-share, global infrastructure and co-commercialization terms structurally reduce execution and commercialization risk for bexobrutideg.
Robust Clinical Data For Lead BTK DegraderConsistent high objective response rates and tolerability across difficult and earlier-line CLL cohorts support best-in-class potential and justify a broad registrational program. Durable clinical differentiation underpins long-term commercial and partnership value across hematology and immunology indications.
Low Leverage With Meaningful Equity CushionModest debt and a sizable equity base provide financial flexibility to fund R&D or pursue partnerships without excessive leverage. This balance sheet strength reduces near-term solvency risk and preserves strategic optionality while the company advances clinical programs.
Bears Say
High And Persistent Cash BurnLarge and sustained negative operating and free cash flow signal ongoing heavy capital consumption to advance programs. Even with recent partnering proceeds, persistent burn requires continued milestone receipts, asset monetization or dilution, constraining long-term financial flexibility and investment scope.
Weak Revenue And Large Net LossesDeclining trailing revenue and a substantial net loss reflect a cost structure that outpaces current commercial receipts. Structural unprofitability risks equity erosion over time and increases dependence on external funding or partnerships to sustain development and commercialization plans.
Milestone-dependent, Partnership-driven Revenue ModelRelying on upfronts, R&D reimbursements and milestone payments creates lumpy, timing-sensitive revenues tied to partner decisions and trial outcomes. This structural concentration elevates execution and cash-flow risk if partners delay or deprioritize programs or if regulatory hurdles arise.
Nurix Therapeutics News
NRIX FAQ
What was Nurix Therapeutics, Inc.’s price range in the past 12 months?
Nurix Therapeutics, Inc. lowest stock price was $8.20 and its highest was $22.50 in the past 12 months.
What is Nurix Therapeutics, Inc.’s market cap?
Nurix Therapeutics, Inc.’s market cap is $1.76B.
When is Nurix Therapeutics, Inc.’s upcoming earnings report date?
Nurix Therapeutics, Inc.’s upcoming earnings report date is Jul 09, 2026 which is in 22 days.
How were Nurix Therapeutics, Inc.’s earnings last quarter?
Nurix Therapeutics, Inc. released its earnings results on Apr 08, 2026. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of -$0.763 by -$0.027.
Is Nurix Therapeutics, Inc. overvalued?
According to Wall Street analysts Nurix Therapeutics, Inc.’s price is currently Undervalued.
Does Nurix Therapeutics, Inc. pay dividends?
Nurix Therapeutics, Inc. does not currently pay dividends.
What is Nurix Therapeutics, Inc.’s EPS estimate?
Nurix Therapeutics, Inc.’s EPS estimate is -0.72.
How many shares outstanding does Nurix Therapeutics, Inc. have?
Nurix Therapeutics, Inc. has 103,405,815 shares outstanding.
What happened to Nurix Therapeutics, Inc.’s price movement after its last earnings report?
Nurix Therapeutics, Inc. reported an EPS of -$0.79 in its last earnings report, missing expectations of -$0.763. Following the earnings report the stock price went down -4.587%.
Which hedge fund is a major shareholder of Nurix Therapeutics, Inc.?
Currently, no hedge funds are holding shares in NRIX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nurix Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$33.00 (88.46% Upside)
$33.00 (88.46% Upside)
Blogger Sentiment
Bullish
NRIX Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Increased
By 658.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 3.3%
Last 30 Days ▼ 1.1%
Last 30 Days ▼ 1.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
42.83%
12-Months-Change
Fundamentals
Return on Equity
-64.21%
Trailing 12-Months
Asset Growth
3.43%
Trailing 12-Months
Company Description
Nurix Therapeutics, Inc.
Nurix Therapeutics, Inc., a biopharmaceutical firm headquartered in San Francisco, California, was founded in 2009. This company, which rebranded from Nurix Inc. in October 2018, is dedicated to the identification, advancement, and commercialization of innovative small molecule treatments for various cancers and immune system disorders. Its robust pipeline features several key drug candidates: NX-2127 and NX-5948: Both are orally administered Bruton's tyrosine kinase (BTK) degraders, targeting B-cell malignancies that have relapsed or are resistant to prior therapies. NX-5948 is also being explored for autoimmune conditions. NX-1607: An orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, developed for immuno-oncology applications. NX-0255: A CBL-B inhibitor designed for ex vivo use to enhance the efficacy of adoptive T-cell therapies. DeTIL-0255: Currently undergoing Phase 1 clinical trials for gynecological cancers, including ovarian, endometrial, and cervical cancers. To further its mission, Nurix has forged significant strategic alliances, notably with Gilead Sciences, Inc. for the development of therapies addressing cancer and other challenging diseases, and also with Sanofi S.A.
NRIX Stock 12 Month Forecast
Average Price Target
$33.00
▲(88.46% Upside)
Technical Analysis
Ownership Overview
0.18% Insiders
17.46% Mutual Funds
58.48% Other Institutional Investors
0.82% Public Companies and
Individual Investors